Printer Friendly

United States : Antares Pharma Appoints Dr. Karen Smith to Board of Directors and Announces Retirement of Dr. Jacques Gonella.

Antares Pharma, Inc. announced the appointment of Dr. Karen Smith to the Companys Board of Directors, filling the seat being vacated by the retirement of Dr. Jacques Gonella. Dr. Smith has over 20 years of biopharmaceutical industry experience in the United States, Europe, Canada and Asia, and currently serves as Chief Executive Officer for Eliminate Cancer (ECI), a cutting-edge oncology R&D and venture organization. Leonard S. Jacob, M.D., Ph.D., Chairman of the Board of Antares Pharma, stated, We are pleased to announce the addition of another seasoned pharmaceutical executive to the Antares Board of Directors. We believe Dr. Smiths background in drug development and product registration will benefit our organization as we continue to expand the Companys pipeline. We look forward to Karens contributions.

Dr. Smith has overseen more than 60 clinical trials and more than 20 regulatory approvals leading to product launches across diverse therapeutic areas including oncology, rare disease, cardiology, dermatology neuroscience and anti-infectives. In addition to R&D and pipeline development, Karens successful record of business development includes the acquisition of U.S. and international companies, divestitures and negotiating partnership deals between biotech and pharma. Prior to joining ECI, Karen served as Executive Vice President, Global Head R&D, and Chief Medical Officer of Jazz Pharmaceuticals, Inc., and also held senior leadership positions at Allergan plc, AstraZeneca and Bristol-Myers Squibb. She is currently a member of the Board of Directors of Acceleron Pharma, ECI and Sangamo Therapeutics. Dr. Smith earned an MD from the University of Warwick (UK), PhD in Molecular Oncology from UCLA (USA) and University of Western Australia (Australia), an MBA from the University of New England in Australia and LLM (Masters in Law) from the University of Salford (UK).

Dr. Jacob continued, The Board of Directors would like to thank Dr. Gonella for eighteen years of dedicated service, first as the founder of Antares Pharma and also as a significant contributor to the development of our Company. He served for eight years as our first Chairman of the Board of Directors. Dr. Gonellas lengthy experience in R&D, operating and financial management as well as his knowledge concerning public companies has provided valuable insight regarding the Companys operations. We wish him well in his retirement.

[c] 2019 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2019 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Mar 7, 2019
Previous Article:Canada : CSC responds to criminal charges laid regarding incidents at Edmonton Institution.
Next Article:Canada : Government of Canada provides Yukon with $2.2 million to help prevent and combat gun and gang violence.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters